PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address key trends in late phase development and Comparative Effectiveness Research at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress, to be held from October 24 - 27, 2009 in Paris, France.

Attendees at the meeting will be able to learn more about capabilities related to these topics by visiting the PAREXEL Stands #87 and #88 in the exhibit hall. PAREXEL representatives will be in attendance to discuss expertise related to all phases of clinical development, reimbursement and market access, and medical communications. In addition, representatives from PAREXEL's subsidiary, Perceptive Informatics, a leading eClinical solutions provider, will be present to discuss the capabilities of its eClinical Suite, including the collection of electronic patient-reported outcomes, to accelerate clinical development.

The ISPOR Annual European Congress program features the following sessions:

Sunday, October 25

• The Role of Patient Registries in Evidence Development: Similarities and Differences Between Europe and North America - Yvonne Lis, Consultant, Peri-Approval Services, PAREXEL (W6: Session I Workshop, 15:15 - 16:15)

• Trends in Comparative Effectiveness of Top 20 Highest Selling Drugs - Saurabh Aggarwal, PhD, Senior Consultant, Reimbursement and Market Access, PAREXEL Consulting (Poster Session I: PHP59, 12:00 - 19:30)

Tuesday, October 27

• Patient Registries - A Literature Review of Recently Reported Registry Based Studies - Yvonne Lis, Consultant, Peri-Approval Services, PAREXEL (Poster Session III: PMC76, 8:00 - 16:00)